A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics

Phase 1

Recruiting

• Conditions: Healthy Participants; Asthma
• Interventions: Drug: Placebo; Drug: IBI3002

• Registration Number: NCT06213844
• Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Brief Summary

This is a single-center, randomized, double-blind, placebo-controlled, phase 1, single-ascending-dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3002 in healthy participants and mild to moderate asthmatics. Subjects will be randomly assigned to different dosages of IBI3002 and matched placebo groups. The entire trial cycle includes a 4-week screening period, 1-day treatment period and 5-week follow-up period.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-01-10
• Study First Submitted QC: 2024-01-10
• Study First Posted: 2024-01-19
• Study Start: 2024-02-26
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-05
• Last Update Posted: 2024-03-07
• Primary Completion: 2025-02-15
• Study Completion: 2025-02-15

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 52

Inclusion Criteria

1. Participants must sign an Institutional Review Board (IRB) approved informed consent form before any study specific procedures.

2. Participants must be between 18 and 55 years old, inclusive.

3. Participants must have a body mass index (BMI) between 18 to 32 kg/m2, inclusive.

4. Participants of childbearing potential and their partners should use highly effective methods of birth control during the study and until 6 months after the study.

5. Participants with asthma must have:

   • Documented physician diagnosis of asthma for at least 12 months prior to screening and confirmed by the investigator;
   • Elevated FeNO defined as ≥ 25ppb;
   • Documented and stable GINA 2023 recommended Step 1~3 controller treatment (defined as ≤ 250μg fluticasone propionate dry powder formulation equivalent total daily dose of ICS, alone or in combination with LABA) for the last 3 months prior to screening;
   • Pre-BD FEV1 ≥ 60% of prediction and Post-BD FEV1/forced vital capacity (FVC) > 70%.

Exclusion Criteria

1. History of allergies to any components of IBI3002 or placebo.
2. History of blood or needle sickness, or those who cannot tolerate venipuncture.
3. Female participants who are pregnant or breastfeeding at screening or randomization.
4. History of participating in a clinical trial within 1 month or 5 half-lives of the test drug (whichever is longer) prior to randomization, or those who are currently participating in a clinical trial.
5. History of severe infection or significant injury within 6 months, or surgery within 3 months, or any infection requiring systemic medication within 1 month prior to screening or randomization.
6. History of live or attenuated vaccination within 1 month prior to randomization, or those who plan to be vaccinated during the study.
7. For asthmatics only: history of a life-threatening asthma attack that required mechanical ventilation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the last 5 years prior to randomization.
8. For asthmatics only: history of asthma worsen or exacerbation resulting in emergency room (ER) visits or overnight hospitalizations, or an increase in asthma maintenance therapy, or use of systemic glucocorticoids within the last 3 months prior to randomization.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Single dose of Placebo administered subcutaneously on Day 1
IBI3002	IBI3002	Single dose of IBI3002 (Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, Dosage 6) administered subcutaneously on Day 1

Primary Outcome Measures

Name	Time	Method
Number of participants with AEs/SAEs	Baseline up to Day 36	Incidence of adverse events and severe adverse events

Secondary Outcome Measures

Name	Time	Method
PK parameter: Cmax	Baseline up to Day 36	Observed maximum plasma concentration
PK parameter: AUC	Baseline up to Day 36	Area under the plasma concentration-time curve
PD profile (only in asthmatics): TARC (CCL17)	Baseline up to Day 36	Change from baseline in peripheral blood TARC (CCL17) level
Clinical profile (only in asthmatics): Spirometry	Baseline up to Day 36	Change from baseline in pre-bronchodilator forced expiratory volume in 1 second (Pre-BD FEV1)
PK parameter: tmax	Baseline up to Day 36	Time to achieve Cmax
PD profile (only in asthmatics): IgE	Baseline up to Day 36	Change from baseline in peripheral blood Immunoglobulin
Immunogenicity profiles	Baseline up to Day 36	Frequency and titers of anti-drug antibody (ADA)
PD profile (only in asthmatics): Eosinophil	Baseline up to Day 36	Change from baseline in peripheral blood eosinophil level
Clinical profile (only in asthmatics): FeNO	Baseline up to Day 36	Change from baseline in Fractional exhaled Nitric Oxide
PD profile (only in asthmatics): IL-13	Baseline up to Day 36	Change from baseline in peripheral blood IL-13 level

Trial Locations

Locations (1)

Nucleus Network Pty Ltd; 🇦🇺 Melbourne, Victoria, Australia